Aortic stenosis

Not to be confused with Coarctation of the aorta.

Aortic stenosis
In the center an aortic valve with severe stenosis due to rheumatic heart disease. The valve is … surrounded by the aorta. The pulmonary trunk is at the upper right. The right coronary artery, cut lengthwise, is at the lower left. The left main coronary artery, also cut lengthwise, is on the right.
Specialty	Cardiac surgery
Symptoms	Decreased ability to exercise, loss of consciousness, shortness of breath, heart related chest pain, leg swelling [1]
Complications	Heart failure [1]
Usual onset	Gradual [1]
Causes	Bicuspid aortic valve, rheumatic fever [1]
Risk factors	Smoking, high blood pressure, high cholesterol, diabetes, being male [1]
Diagnostic method	Ultrasound of the heart [1]
Treatment	Aortic valve replacement, balloon aortic valvuloplasty [1]
Prognosis	Five-year survival ~50% without treatment in symptomatic patients [1]
Frequency	2% of people over 65 (developed world) [1]

Aortic stenosis (AS or AoS) is the narrowing of the exit of the left ventricle of the heart (where the aorta begins), such that problems result. ^[1] It may occur at the aortic valve as well as above and below this level. ^[1] It typically gets worse over time. ^[1] Symptoms often come on gradually with a decreased ability to exercise often occurring first. ^[1] If heart failure, loss of consciousness, or heart related chest pain occur due to AS the outcomes are worse. ^[1] Loss of consciousness typically occurs with standing or exercising. ^[1] Signs of heart failure include shortness of breath especially when lying down, at night, or with exercise, and swelling of the legs. ^[1] Thickening of the valve without causing obstruction is known as aortic sclerosis. ^[1]

Causes include being born with a bicuspid aortic valve, and rheumatic fever; a normal valve may also harden over the decades due to calcification. ^{[2] [1]} A bicuspid aortic valve affects about one to two percent of the population. ^[1] As of 2014 rheumatic heart disease mostly occurs in the developing world. ^[1] Risk factors are similar to those of coronary artery disease and include smoking, high blood pressure, high cholesterol, diabetes, and being male. ^[1] The aortic valve usually has three leaflets and is located between the left ventricle of the heart, and the aorta. ^[1] AS typically results in a heart murmur. ^[1] Its severity can be divided into mild, moderate, severe, and very severe, distinguishable by ultrasound scan of the heart. ^[1]

Aortic stenosis is typically followed using repeated ultrasound scans. ^[1] Once it has become severe, treatment primarily involves valve replacement surgery, with transcatheter aortic valve replacement (TAVR) being an option in some who are at high risk from surgery. ^[1] Valves may either be mechanical or bioprosthetic, with each having risks and benefits. ^[1] Another less invasive procedure, balloon aortic valvuloplasty (BAV), may result in benefit, but for only a few months. ^[1] Complications such as heart failure may be treated in the same way as in those with mild to moderate AS. ^[1] In those with severe disease a number of medications should be avoided, including ACE inhibitors, nitroglycerin, and some beta blockers. ^[1] Nitroprusside or phenylephrine may be used in those with decompensated heart failure depending on the blood pressure. ^{[1] [3]}

Aortic stenosis is the most common valvular heart disease in the developed world. ^[4] It affects about 2% of people who are over 65 years of age. ^[1] Estimated rates were not known in most of the developing world as of 2014. ^[5] In those who have symptoms, without repair the chance of death at five years is about 50% and at 10 years is about 90%. ^[1] Aortic stenosis was first described by French physician Lazare Rivière in 1663. ^[6]

Signs and symptoms

Symptoms related to aortic stenosis depend on the degree of stenosis. Most people with mild to moderate aortic stenosis do not have symptoms. Symptoms usually present in individuals with severe aortic stenosis, though they may also occur in those with mild to moderate aortic stenosis. The three main symptoms of aortic stenosis are loss of consciousness, anginal chest pain and shortness of breath with activity or other symptoms of heart failure such as shortness of breath while lying flat, episodes of shortness of breath at night, or swollen legs and feet. ^{[4] [7]} It may also be accompanied by the characteristic "Dresden china" appearance of pallor with a light flush. ^{[8] [ clarification needed ]}

Angina

Angina in setting of heart failure also increases the risk of death. In people with angina, the 5-year mortality rate is 50% if the aortic valve is not replaced. ^[9]

Angina in the setting of AS occurs due to left ventricular hypertrophy (LVH) that is caused by the constant production of increased pressure required to overcome the pressure gradient caused by the AS. While the muscular layer of the left ventricle thickens, the arteries that supply the muscle do not get significantly longer or bigger, so the muscle may not receive enough blood supply to meet its oxygen requirement. This ischemia may first be evident during exercise when the heart muscle requires increased blood supply to compensate for the increased workload. The individual may complain of anginal chest pain with exertion. Exercise stress testing with or without imaging is strictly contraindicated in symptomatic patients with severe aortic stenosis. Exercise stress test is now recommended by current guidelines in asymptomatic patients and may provide incremental prognostic value. ^[10]

Eventually, however, the heart muscle will require more blood supply at rest than can be supplied by the coronary artery branches. At this point there may be signs of ventricular strain pattern (ST segment depression and T wave inversion) on the EKG, suggesting subendocardial ischemia. The subendocardium is the region that is most susceptible to ischemia because it is the most distant from the epicardial coronary arteries. ^[11]

Syncope

Syncope (fainting spells) from aortic valve stenosis is usually exertional. ^{[4] [12]} In the setting of heart failure it increases the risk of death. In people with syncope, the three-year mortality rate is 50% if the aortic valve is not replaced. ^[13]

It is unclear why aortic stenosis causes syncope. One theory is that severe AS produces a nearly fixed cardiac output. ^[14] When a person with aortic stenosis exercises, their peripheral vascular resistance will decrease as the blood vessels of the skeletal muscles dilate to allow the muscles to receive more blood to allow them to do more work. This decrease in peripheral vascular resistance is normally compensated for by an increase in the cardiac output. Since people with severe AS cannot increase their cardiac output, the blood pressure falls and the person will faint due to decreased blood perfusion to the brain. ^[15]

A second theory is that during exercise the high pressures generated in the hypertrophied left ventricle cause a vasodepressor response, which causes a secondary peripheral vasodilation that, in turn, causes decreased blood flow to the brain resulting in loss of consciousness. Indeed, in aortic stenosis, because of the fixed obstruction to blood flow out from the heart, it may be impossible for the heart to increase its output to offset peripheral vasodilation.^{[ citation needed ]}

A third mechanism may sometimes be operative. Due to the hypertrophy of the left ventricle in aortic stenosis, including the consequent inability of the coronary arteries to adequately supply blood to the myocardium (see "Angina" below), abnormal heart rhythms may develop. These can lead to syncope. ^[16]

Finally, in calcific aortic stenosis ^{[17] [18]} at least, the calcification in and around the aortic valve can progress and extend to involve the electrical conduction system of the heart. If that occurs, the result may be heart block, a potentially lethal condition of which syncope may be a symptom.^{[ citation needed ]}

Congestive heart failure

Congestive heart failure (CHF) carries a grave prognosis in people with AS. People with CHF attributable to AS have a 2-year mortality rate of 50% if the aortic valve is not replaced.^{[ citation needed ]} CHF in the setting of AS is due to a combination of left ventricular hypertrophy with fibrosis, systolic dysfunction (a decrease in the ejection fraction) and diastolic dysfunction (elevated filling pressure of the LV). ^[4]

Associated symptoms

In Heyde's syndrome, aortic stenosis is associated with gastrointestinal bleeding due to angiodysplasia of the colon. ^[19] Recent research has shown that the stenosis causes a form of von Willebrand disease by breaking down its associated coagulation factor (factor VIII-associated antigen, also called von Willebrand factor), ^[20] due to increased turbulence around the stenotic valve.

Complications

Notwithstanding the foregoing^{[ clarification needed ]}, the American Heart Association changed its recommendations regarding antibiotic prophylaxis for endocarditis. Specifically, as of 2007 it is recommended that such prophylaxis should be limited only to those with prosthetic heart valves, those with previous episode(s) of endocarditis, and those with certain types of congenital heart disease. ^[21]

Since the stenosed aortic valve may limit the heart's output, people with aortic stenosis are at risk of syncope and dangerously low blood pressure should they use any of a number of medications for cardiovascular diseases that often coexist with aortic stenosis. Examples include nitroglycerin, nitrates, ACE inhibitors, terazosin (Hytrin), and hydralazine. Note that all of these substances lead to peripheral vasodilation. Under normal circumstances, in the absence of aortic stenosis, the heart is able to increase its output and thereby offset the effect of the dilated blood vessels. In some cases of aortic stenosis, however, due to the obstruction of blood flow out of the heart caused by the stenosed aortic valve, cardiac output cannot be increased. Low blood pressure or syncope may ensue.^{[ citation needed ]}

Causes

Illustration depicting aortic stenosis

Aortic stenosis is most commonly caused by age-related progressive calcific aortic valve disease (CAVD) (>50% of cases), with a mean age of 65 to 70 years. CAVD is the build-up of calcium on the cusps of the valve, and this calcification causes hardening and stenosis of the valve. ^[22] Another major cause of aortic stenosis is the calcification of a congenital bicuspid aortic valve or, more rarely, a congenital unicuspid aortic valve. Those with unicuspid aortic valves typically need intervention when very young, often as a newborn. While those with congenital bicuspid aortic valve make up 30-40% of those presenting during adulthood ^[23] and typically presenting earlier (ages 40+ to 50+) than those with tricuspid aortic valves (65+). ^[7]

Acute rheumatic fever post-inflammatory is the cause of less than 10% of cases. ^[24] Rare causes of aortic stenosis include Fabry disease, systemic lupus erythematosus, Paget disease, high blood uric acid levels, and infection. ^[25]

Pathophysiology

Density-dependent colour scanning electron micrograph of cardiovascular calcification, showing in orange calcium phosphate spherical particles (denser material) and, in green, the extracellular matrix (less dense material).

The human aortic valve normally consists of three cusps or leaflets and has an opening of 3.0-4.0 square centimeters. ^{[6] [25]} When the left ventricle contracts, it forces blood through the valve into the aorta and subsequently to the rest of the body. When the left ventricle expands again, the aortic valve closes and prevents the blood in the aorta from flowing backward (regurgitation) into the left ventricle. In aortic stenosis, the opening of the aortic valve becomes narrowed or constricted (stenotic) (e.g., due to calcification). Degenerative (the most common variety), and bicuspid aortic stenosis both begin with damage to endothelial cells from increased mechanical stress. ^{[7] [25]} Inflammation is thought to be involved in the earlier stages of the pathogenesis of AS and its associated risk factors are known to promote the deposition of LDL cholesterol and lipoprotein(a), a highly damaging substance, into the aortic valve, causing significant damage and stenosis over time. ^{[7] [25]} Infiltration of inflammatory cells (macrophages, T lymphocytes), followed by the release of inflammatory mediators such as interleukin-1-beta and transforming growth factor beta-1 occurs. Subsequently, fibroblasts differentiate into osteoblast-like cells, which results in abnormal bone matrix deposition leading to progressive valvular calcification and stenosis. ^[26]

As a consequence of this stenosis, the left ventricle must generate a higher pressure with each contraction to effectively move blood forward into the aorta. ^{[4] [27]} Initially, the LV generates this increased pressure by thickening its muscular walls (myocardial hypertrophy). The type of hypertrophy most commonly seen in AS is known as concentric hypertrophy, ^[4] in which the walls of the LV are (approximately) equally thickened.

In the later stages, the left ventricle dilates, the wall thins, and the systolic function deteriorates (resulting in impaired ability to pump blood forward). Morris and Innasimuthu et al. showed that different coronary anatomy is associated with different valve diseases. Research was in progress in 2010 to see if different coronary anatomy might lead to turbulent flow at the level of valves leading to inflammation and degeneration. ^{[28] [29] [30]}

Diagnosis

Phonocardiograms from normal and abnormal heart sounds

Simultaneous left ventricular and aortic pressure tracings to demonstrate a pressure gradient between the left ventricle and aorta, suggesting aortic stenosis. The left ventricle generates higher pressures than what is transmitted to the aorta. The pressure gradient, caused by aortic stenosis, is represented by the green shaded area. (AO = ascending aorta; LV = left ventricle; ECG = electrocardiogram.)

Palpation

Aortic stenosis is most often diagnosed when it is asymptomatic and can sometimes be detected during routine examination of the heart and circulatory system. Good evidence exists to demonstrate that certain characteristics of the peripheral pulse can rule in the diagnosis. ^[31] In particular, there may be a slow and/or sustained upstroke of the arterial pulse, and the pulse may be of low volume. This is sometimes referred to as pulsus parvus et tardus . ^{[12] [24]} There may also be a noticeable delay between the first heart sound (on auscultation) and the corresponding pulse in the carotid artery ('apical-carotid delay'). In a similar manner, there may be a delay between the appearance of each pulse in the brachial artery (in the arm) and the radial artery (in the wrist).^{[ citation needed ]}

Auscultation

The first heart sound may be followed by a sharp ejection sound ("ejection click") best heard at the lower left sternal border and the apex, and, thus, appear to be "split". The ejection sound, caused by the impact of left ventricular outflow against the partially fused aortic valve leaflets, is more commonly associated with a mobile bicuspid aortic valve than an immobile calcified aortic valve. The intensity of this sound does not vary with respiration, which helps distinguish it from the ejection click produced by a stenotic pulmonary valve, which will diminish slightly in intensity during inspiration. ^[32]

An easily heard systolic, crescendo-decrescendo (i.e., 'ejection') murmur is heard loudest at the upper right sternal border, at the 2nd right intercostal space, ^[24] and radiates to the carotid arteries bilaterally. ^{[4] [12]} The murmur increases with squatting and decreases with standing and isometric muscular contraction such as the Valsalva maneuver, which helps distinguish it from hypertrophic obstructive cardiomyopathy (HOCM). The murmur is louder during expiration but is also easily heard during inspiration. The more severe the degree of the stenosis, the later the peak occurs in the crescendo-decrescendo of the murmur. ^[33]

The second heart sound (A₂) tends to become decreased and softer as the aortic stenosis becomes more severe. ^[24] This is a result of the increasing calcification of the valve preventing it from "snapping" shut and producing a sharp, loud sound. Due to increases in left ventricular pressure from the stenotic aortic valve, over time the ventricle may hypertrophy, resulting in diastolic dysfunction. As a result, there may be a fourth heart sound due to the stiff ventricle. ^[12] With continued increases in ventricular pressure, dilatation of the ventricle will occur, and a third heart sound may be manifest. ^[34]

Finally, aortic stenosis often co-exists with some degree of aortic insufficiency (aortic regurgitation). Hence, the physical exam in aortic stenosis may also reveal signs of the latter, for example, an early diastolic decrescendo murmur. Indeed, when both valve abnormalities are present, the expected findings of either may be modified or may not even be present. Rather, new signs that reflect the presence of simultaneous aortic stenosis and insufficiency, e.g., pulsus bisferiens, emerge.^{[ citation needed ]}

According to a meta-analysis, the most useful findings for ruling in aortic stenosis in the clinical setting were slow rate of rise of the carotid pulse (positive likelihood ratio ranged 2.8–130 across studies), mid to late peak intensity of the murmur (positive likelihood ratio, 8.0–101), and decreased intensity of the second heart sound (positive likelihood ratio, 3.1–50). ^[31]

Other peripheral signs include:^{[ citation needed ]}

• sustained, heaving apex beat, ^[12] which is not displaced unless systolic dysfunction of the left ventricle has developed
• A precordial thrill ^[12]
• narrowed pulse pressure

Blood tests

For asymptomatic severe aortic valve stenosis, the European guidelines ^[35] recommend B-type natriuretic peptide (BNP) measurements to aid risk stratification and optimize the timing of aortic valve replacement surgery. ^{[36] [37]} In patients with non-severe asymptomatic aortic valve stenosis, increased age- and sex adjusted N-terminal pro-brain natriuretic peptide (NT-proBNP) levels alone and combined with a 50% or greater increase from baseline had been found associated with increased event rates of aortic valve stenosis related events (cardiovascular death, hospitalization with heart failure due to progression of aortic valve stenosis, or aortic valve replacement surgery). ^[38] In patients with non-severe asymptomatic aortic valve stenosis and no overt coronary artery disease, the increased troponin T (above 14 pg/mL) was found associated with an increased 5-year event rate of ischemic cardiac events (myocardial infarction, percutaneous coronary intervention, or coronary artery bypass surgery). ^[39]

Electrocardiogram

Although aortic stenosis does not lead to any specific findings on the electrocardiogram (ECG), it still often leads to a number of electrocardiographic abnormalities. ECG manifestations of left ventricular hypertrophy (LVH) are common in aortic stenosis ^{[7] [12]} and arise as a result of the stenosis having placed a chronically high-pressure load on the left ventricle (with LVH being the expected response to chronic pressure loads on the left ventricle no matter what the cause). ^[40]

As noted above, the calcification process that occurs in aortic stenosis can progress to extend beyond the aortic valve and into the electrical conduction system of the heart. Evidence of this phenomenon may rarely include ECG patterns characteristic of certain types of heart block such as Left bundle branch block. ^[7]

Heart catheterization

Cardiac chamber catheterization provides a definitive diagnosis, indicating severe stenosis in valve area of <1.0 cm² (normally about 3 cm²). ^[41] It can directly measure the pressure on both sides of the aortic valve. The pressure gradient may be used as a decision point for treatment. It is useful in symptomatic people before surgery. ^[12] The standard for diagnosis of aortic stenosis is non-invasive testing with echocardiography. Cardiac catheterization is reserved for cases in which there is a discrepancy between the clinical picture and non-invasive testing, due to risks inherent to crossing the aortic valve, such as stroke. ^[7]

Echocardiogram

Severity of aortic stenosis [24]
Degree	Mean gradient (mmHg)	Aortic valve area (cm2)
Mild	<25	>1.5
Moderate	25 - 40	1.0 - 1.5
Severe	>40	< 1.0
Very severe	>70	< 0.6

Echocardiogram (heart ultrasound) is the best non-invasive way to evaluate the aortic valve anatomy and function. ^[42]

The aortic valve area can be calculated non-invasively using echocardiographic flow velocities. Using the velocity of the blood through the valve, the pressure gradient across the valve can be calculated by the continuity equation or using the modified Bernoulli's equation:

Gradient = 4(velocity)² mmHg

A normal aortic valve has a gradient of only a few mmHg. A decreased valvular area causes increased pressure gradient, and these parameters are used to classify and grade the aortic stenosis as mild, moderate or severe. The pressure gradient can be abnormally low in the presence of mitral stenosis, heart failure, co-existent aortic regurgitation and also ischaemic heart disease (disease related to the decreased blood supply and oxygen causing ischemia). ^[43]

Echocardiogram may also show left ventricular hypertrophy, thickened and immobile aortic valve, and dilated aortic root. ^[12] However, it may appear deceptively normal in acute cases. ^[24]

Chest X-ray

A chest X-ray can also assist in the diagnosis and provide clues as to the severity of the disease, showing the degree of calcification of the valve, and in a chronic condition, an enlarged left ventricle ^{[12] [24]} and atrium. ^[12]

Computer tomography

The use of CT calcium scoring is gaining spread as a diagnostic tool to complement echo in the assessment of patients with aortic stenosis. ^{[44] [45]} Aortic valve calcium scoring by multidetector computed tomography (CT-AVC) is used to quantify the degree of calcification of the aortic valve. ^[46] According to the 2021 ESC/EACTS Guidelines for the management of valvular heart disease the recommended thresholds indicating severe aortic stenosis are > 1200 AU in women and > 2000 AU in men. ^[47]

Management

Treatment is generally not necessary in people without symptoms. ^[12] In moderate cases echocardiography is performed every 1–2 years to monitor the progression, possibly complemented with a cardiac stress test. ^[24] In severe cases, echocardiography is performed every 3–6 months. ^[24] In both moderate and mild cases, the person should immediately make a revisit or be admitted for inpatient care if any new related symptoms appear. ^[24] There are no therapeutic options currently available to treat people with aortic valve stenosis; however, studies in 2014 indicated that the disease occurs as a result of active cellular processes, suggesting that targeting these processes may lead to viable therapeutic approaches. ^[48]

Medication

Observational studies demonstrated an association between lowered cholesterol with statins and decreased progression, but a randomized clinical trial published in 2005 failed to find any effect on calcific aortic stenosis. The effect of statins on the progression of AS is unclear. A 2007 study found a slowing of aortic stenosis with rosuvastatin. ^{[7] [49]} In 2013 it was reported that trials did not show any benefit in slowing AS progression, ^[7] but did demonstrate a decrease in ischemic cardiovascular events. ^[4]

In general, medical therapy has relatively poor efficacy in treating aortic stenosis. ^[12] However, it may be useful to manage commonly coexisting conditions that correlate with aortic stenosis: ^[50]

• Any angina is generally treated with beta-blockers and/or calcium blockers. ^[24] Nitrates are contraindicated due to their potential to cause profound hypotension in aortic stenosis. ^[51]
• Any hypertension is treated aggressively, but caution must be taken in administering beta-blockers. ^[24] The optimal blood pressure in patients with asymptomatic aortic stenosis and no manifest atherosclerotic disease or diabetes mellitus was found to be a systolic blood pressure of 130-139 mmHg and a diastolic blood pressure of 70-90 mmHg. ^[52]
• Any heart failure is generally treated with digoxin and diuretics, and, if not contraindicated, cautious administration of ACE inhibitors. ^[24]

Aortic valve repair

Main article: Aortic valve repair

Aortic valve repair or aortic valve reconstruction describes the reconstruction of both form and function of the native and dysfunctioning aortic valve. Most frequently it is applied for the treatment of aortic regurgitation. It can also become necessary for the treatment of an aortic aneurysm, less frequently for congenital aortic stenosis. ^[53]  

Aortic valve replacement

Main article: Aortic valve replacement

In adults, symptomatic severe aortic stenosis usually requires aortic valve replacement (AVR). ^[4] While Surgical AVR has remained the most effective treatment for this disease process and is currently recommended for patients after the onset of symptoms, as of 2016 ^[update] aortic valve replacement approaches included open-heart surgery, minimally invasive cardiac surgery (MICS), and minimally invasive catheter-based (percutaneous) aortic valve replacement. ^{[54] [55] [56]} However, surgical aortic valve replacement is well-studied, and generally has a good and well-established longer-term prognosis. ^[57]

A diseased aortic valve is most commonly replaced using a surgical procedure with either a mechanical or a tissue valve. The procedure is done either in an open-heart surgical procedure or, in a smaller but growing number of cases, a minimally invasive cardiac surgery (MICS) procedure.^{[ citation needed ]} Minimally invasive approach via right minithoracotomy is most beneficial in the high risk patient such as the elderly, the obese, those with chronic obstructive pulmonary, chronic kidney disease and those requiring re-operative surgery. ^{[58] [59]}

Transcatheter aortic valve replacement

Globally more than 250,000 people have received transcatheter aortic valve intervention (TAVI). For people who are not candidates for surgical valve replacement and most patients who are older than 75, TAVI may be a suitable alternative. ^{[54] [55]} Conduction abnormalities requiring permanent pacemaker (PPM) implantation remain a common finding after TAVI due to the close proximity of the atrioventricular conduction system to the aortic root. ^[60]

Balloon valvuloplasty

For infants and children, balloon valvuloplasty, where a balloon is inflated to stretch the valve and allow greater flow, may also be effective. In adults, however, it is generally ineffective, as the valve tends to return to a stenosed state. The surgeon will make a small incision at the top of the person's leg and proceed to insert the balloon into the artery. The balloon is then advanced up to the valve and is inflated to stretch the valve open. ^[61]

Heart failure

Acute decompensated heart failure due to AS may be temporarily managed by an intra-aortic balloon pump while pending surgery. ^[62] In those with high blood pressure nitroprusside may be carefully used. ^[1] Phenylephrine may be used in those with very low blood pressure. ^[3]

Prognosis

If untreated, severe symptomatic aortic stenosis carries a poor prognosis, with a 2-year mortality rate of 50-60% and a 3-year survival rate of less than 30%. ^[63] Prognosis after aortic valve replacement for people younger than 65 is about five years less than that of the general population; for people older than 65 it is about the same. ^[57]

Epidemiology

Approximately 2% of people over the age of 65, 3% of people over age 75, ^[4] and 4% percent of people over age 85 have aortic valve stenosis. ^[64] The prevalence is increasing with the aging population in North America and Europe. ^[65]

Risk factors known to influence disease progression of AS include factors similar to those of coronary artery disease such as hypertension, advanced age, being male, hyperlipidemia, diabetes mellitus, cigarette smoking, metabolic syndrome, and end-stage kidney disease. ^{[4] [7] [25]}

History

Aortic stenosis was first described by French physician Lazare Rivière in 1663. ^[6]

Research

People on bisphosphonates were found in a 2010 study to have less progression of aortic stenosis, and some regressed. ^{[66] [67]} This finding led to multiple trials, ongoing as of 2012 ^[update] . Subsequent research failed to confirm the initial positive result. ^[68]

References

1. Czarny, MJ; Resar, JR (2014). "Diagnosis and management of valvular aortic stenosis". Clinical Medicine Insights. Cardiology. 8 (Suppl 1): 15–24. doi: 10.4137/CMC.S15716 . PMC   4213201 . PMID   25368539.
2. Bertazzo, Sergio; Gentleman, Eileen; Cloyd, Kristy L.; Chester, Adrian H.; Yacoub, Magdi H.; Stevens, Molly M. (2013). "Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification". Nature Materials. 12 (6): 576–583. Bibcode:2013NatMa..12..576B. doi:10.1038/nmat3627. ISSN   1476-1122. PMC   5833942 . PMID   23603848.
3. Overgaard, CB; Dzavík, V (2 September 2008). "Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease". Circulation. 118 (10): 1047–56. doi: 10.1161/CIRCULATIONAHA.107.728840 . PMID   18765387.
4. Manning WJ (October 2013). "Asymptomatic aortic stenosis in the elderly: a clinical review". JAMA. 310 (14): 1490–7. doi:10.1001/jama.2013.279194. PMID   24104373. S2CID   205041976.
5. Thaden, JJ; Nkomo, VT; Enriquez-Sarano, M (2014). "The global burden of aortic stenosis". Progress in Cardiovascular Diseases. 56 (6): 565–71. doi:10.1016/j.pcad.2014.02.006. PMID   24838132.
6. Leopold JA (August 2012). "Cellular mechanisms of aortic valve calcification". Circulation: Cardiovascular Interventions. 5 (4): 605–14. doi:10.1161/CIRCINTERVENTIONS.112.971028. PMC   3427002 . PMID   22896576.
7. Rogers, FJ (November 2013). "Aortic stenosis: new thoughts on a cardiac disease of older people". Journal of the American Osteopathic Association. 113 (11): 820–828. doi: 10.7556/jaoa.2013.057 . PMID   24174503.
8. Silverman, ME (April 1999). "A view from the millennium: the practice of cardiology circa 1950 and thereafter". Journal of the American College of Cardiology. 33 (5): 1141–51. doi: 10.1016/s0735-1097(99)00027-3 . PMID   10193710.
9. "Aortic Stenosis". The Lecturio Medical Concept Library. Retrieved 30 June 2021.
10. Magne J, Lancellotti P, Piérard LA. Exercise testing in asymptomatic severe aortic stenosis. JACC Cardiovasc Imaging. 2014 Feb;7(2):188-99. doi: 10.1016/j.jcmg.2013.08.011. PMID 24524744.
11. Algranati D, Kassab GS, Lanir Y. Why is the subendocardium more vulnerable to ischemia? A new paradigm. Am J Physiol Heart Circ Physiol. 2011;300(3):H1090-H1100. doi:10.1152/ajpheart.00473.2010
12. Chapter 1: Diseases of the Cardiovascular system > Section: Valvular Heart Disease in: Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series) . Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN   978-0-7817-7153-5.^{[ page needed ]}
13. Blase A. Carabello. (2002). "Evaluation and management of patients with aortic stenosis". Circulation. 105 (15): 1746–1750. doi: 10.1161/01.cir.0000015343.76143.13 . PMID   11956110.
14. Richards, Mark; Ikram, Hamid; Nicholls, M. Gary; Hamilton, Eric; Richards, Rosemary (1984). "Syncope in aortic valvular stenosis". The Lancet. 324 (8412): 1113–1116. doi:10.1016/S0140-6736(84)91555-1. PMID   6150181. S2CID   23132191.
15. Richards AM, Nicholls MG, Ikram H, Hamilton EJ, Richards RD. Syncope in aortic valvular stenosis. Lancet. 1984 Nov 17;2(8412):1113-6. doi: 10.1016/s0140-6736(84)91555-1. PMID 6150181.
16. Seger JJ. Syncope evaluation and management. Tex Heart Inst J. 2005;32(2):204-206.
17. Bertazzo S, Gentleman E, Cloyd KL, Chester AH, Yacoub MH, Stevens MM (June 2013). "Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification". Nature Materials. 12 (6): 576–83. Bibcode:2013NatMa..12..576B. doi:10.1038/nmat3627. PMC   5833942 . PMID   23603848.
18. Miller JD (June 2013). "Cardiovascular calcification: Orbicular origins". Nature Materials. 12 (6): 476–8. Bibcode:2013NatMa..12..476M. doi:10.1038/nmat3663. PMID   23695741.
19. Figuinha, FC; Spina, GS; Tarasoutchi, F (March 2011). "Heyde's syndrome: case report and literature review". Arquivos Brasileiros de Cardiologia. 96 (3): e42–e45. doi: 10.1590/S0066-782X2011000300017 . PMID   21484065.
20. Horiuchi, Hisanori; Doman, Tsuyoshi; Kokame, Koichi; Saiki, Yoshikatsu; Matsumoto, Masanori (2019). "Acquired von Willebrand Syndrome Associated with Cardiovascular Diseases". Journal of Atherosclerosis and Thrombosis. 26 (4): 303–314. doi:10.5551/jat.RV17031. ISSN   1340-3478. PMC   6456452 . PMID   30867356.
21. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Oct 9;116(15):1736-54. doi: 10.1161/CIRCULATIONAHA.106.183095. Epub 2007 Apr 19. Erratum in: Circulation. 2007 Oct 9;116(15):e376-7. PMID 17446442.
22. Zhu, Z; Liu, Z; Zhang, D; Li, L; Pei, J; Cai, L (1 March 2024). "Models for calcific aortic valve disease in vivo and in vitro". Cell Regeneration (London, England). 13 (1): 6. doi: 10.1186/s13619-024-00189-8 . PMC   10904700 . PMID   38424219.
23. Zalaquett S, Ricardo; Camplá C, Cristóbal; Scheu G, Maximiliano; Córdova A, Samuel; Becker R, Pedro; Morán V, Sergio; Irarrázaval Ll, Manuel J; Baeza P, Cristian; Arretz V, Claudio; Braun J, Sandra; Chamorro S, Gastón; Godoy J, Iván; Yáñez D, Fernando (March 2005). "Ciruguía reparadora de la válvula aórtica bicúspide insuficiente". Revista médica de Chile. 133 (3). doi: 10.4067/S0034-98872005000300002 .
24. VOC=VITIUM ORGANICUM CORDIS, a compendium of the Department of Cardiology at Uppsala Academic Hospital. By Per Kvidal September 1999, with revision by Erik Björklund May 2008
25. Olszowska, Maria (1 November 2011). "Pathogenesis and pathophysiology of aortic valve stenosis in adults". Polish Archives of Internal Medicine. 121 (11): 409–413. doi: 10.20452/pamw.1103 . PMID   22129836. S2CID   7629351.
26. Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation. 2001 Mar 20;103(11):1522-8. doi: 10.1161/01.cir.103.11.1522. PMID 11257079.
27. Lilly LS, ed. (2003). Pathophysiology of Heart Disease (3rd ed.). Lippincott Williams & Wilkins. ISBN   978-0-7817-4027-2.
28. Morris, G.; Innasimuthu, A.L.; Fox, J.P.; Perry, R.A. (2 September 2009). "The association of heart valve diseases with a dominant left coronary circulation". European Heart Journal. 30 (Supplement 1): 682. doi: 10.1093/eurheartj/ehp415 .
29. Morris GM, Innasimuthu AL, Fox JP, Perry RA (May 2010). "The association of heart valve diseases with coronary artery dominance". The Journal of Heart Valve Disease. 19 (3): 389–93. PMID   20583404.
30. Innasimuthu, A.; Morris, G.; Rao, G.; Fox, J.; Perry, R. (1 June 2007). "Left Dominant Coronary arterial system and Aortic stenosis: an association, cause or effect". Heart. 93 (suppl 1): A39.
31. Etchells E, Bell C, Robb K (February 1997). "Does this patient have an abnormal systolic murmur?". JAMA. 277 (7): 564–71. doi:10.1001/jama.277.7.564. PMID   9032164.
32. Lilly, Leonard S., ed. (2007). Pathophysiology of heart disease : a collaborative project of medical students and faculty (4th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p.  36. ISBN   978-0-7817-6321-9.
33. Alpert MA. Systolic Murmurs. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 26. Available from: https://www.ncbi.nlm.nih.gov/books/NBK345/
34. Silverman ME. The Third Heart Sound. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 24. Available from: https://www.ncbi.nlm.nih.gov/books/NBK342/
35. Vahanian, Alec; Beyersdorf, Friedhelm; Praz, Fabien; Milojevic, Milan; Baldus, Stephan; Bauersachs, Johann; Capodanno, Davide; Conradi, Lenard; De Bonis, Michele; De Paulis, Ruggero; Delgado, Victoria; Freemantle, Nick; Gilard, Martine; Haugaa, Kristina H; Jeppsson, Anders (2022-02-12). "2021 ESC/EACTS Guidelines for the management of valvular heart disease". European Heart Journal. 43 (7): 561–632. doi:10.1093/eurheartj/ehab395. ISSN   0195-668X. PMID   34453165.
36. Bergler-Klein, Jutta; Klaar, Ursula; Heger, Maria; Rosenhek, Raphael; Mundigler, Gerald; Gabriel, Harald; Binder, Thomas; Pacher, Richard; Maurer, Gerald; Baumgartner, Helmut (2004-05-18). "Natriuretic Peptides Predict Symptom-Free Survival and Postoperative Outcome in Severe Aortic Stenosis". Circulation. 109 (19): 2302–2308. doi:10.1161/01.CIR.0000126825.50903.18. ISSN   0009-7322.
37. Clavel, Marie-Annick; Malouf, Joseph; Michelena, Hector I.; Suri, Rakesh M.; Jaffe, Allan S.; Mahoney, Douglas W.; Enriquez-Sarano, Maurice (2014-05-20). "B-Type Natriuretic Peptide Clinical Activation in Aortic Stenosis: Impact on Long-Term Survival". Journal of the American College of Cardiology. 63 (19): 2016–2025. doi:10.1016/j.jacc.2014.02.581. hdl: 20.500.11794/2068 . ISSN   0735-1097. PMID   24657652.
38. Hadziselimovic, Edina; Greve, Anders M.; Sajadieh, Ahmad; Olsen, Michael H.; Kesäniemi, Y. Antero; Nienaber, Christoph A.; Ray, Simon G.; Rossebø, Anne B.; Willenheimer, Ronnie; Wachtell, Kristian; Nielsen, Olav W. (2022-04-01). "Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial". JAMA Cardiology. 7 (4): 435–444. doi:10.1001/jamacardio.2021.5916. ISSN   2380-6583. PMC   8851368 . PMID   35171199.
39. Hadziselimovic, Edina; Greve, Anders M.; Sajadieh, Ahmad; Olsen, Michael H.; Kesäniemi, Y. Antero; Nienaber, Christoph A.; Ray, Simon G.; Rossebø, Anne B.; Wachtell, Kristian; Nielsen, Olav W. (April 2023). "Association of high-sensitivity troponin T with outcomes in asymptomatic non-severe aortic stenosis: a post-hoc substudy of the SEAS trial". eClinicalMedicine. 58: 101875. doi:10.1016/j.eclinm.2023.101875. ISSN   2589-5370. PMC   10006443 . PMID   36915288.
40. Vranic II. Electrocardiographic appearance of aortic stenosis before and after aortic valve replacement. Ann Noninvasive Electrocardiol. 2017;22(5):e12457. doi:10.1111/anec.12457
41. "Senile aortic stenosis". Yale atlas of echocardiography. 1999. Archived from the original on November 30, 2012.
42. Płońska-Gościniak, E; Lichodziejewska, B; Szyszka, A; Kukulski, T; Kasprzak, J; Dzikowska-Diduch, O; Gackowski, A; Gościniak, P; Pysz, P; Gąsior1, Z (2019). "Echocardiography in adults". Journal of Ultrasonography. 19 (76): 54–61. doi:10.15557/JoU.2019.0008. PMC   6750174 . PMID   31088012.
43. Zoghbi WA. Low-gradient "severe" aortic stenosis with normal systolic function: time to refine the guidelines? Circulation. 2011 Mar 1;123(8):838-40. doi: 10.1161/CIRCULATIONAHA.110.015826. Epub 2011 Feb 14. PMID 21321159.
44. Otto, Catherine M.; Nishimura, Rick A.; Bonow, Robert O.; Carabello, Blase A.; Erwin, John P.; Gentile, Federico; Jneid, Hani; Krieger, Eric V.; Mack, Michael; McLeod, Christopher; O'Gara, Patrick T. (2021-02-02). "2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 143 (5): e72–e227. doi: 10.1161/CIR.0000000000000923 . ISSN   0009-7322. PMID   33332150. S2CID   229316533.
45. Beyersdorf, Friedhelm; Vahanian, Alec; Milojevic, Milan; Praz, Fabien; Baldus, Stephan; Bauersachs, Johann; Capodanno, Davide; Conradi, Lenard; De Bonis, Michele; De Paulis, Ruggero; Delgado, Victoria (2021-10-22). "2021 ESC/EACTS Guidelines for the management of valvular heart disease". European Journal of Cardio-Thoracic Surgery. 60 (4): 727–800. doi: 10.1093/ejcts/ezab389 . hdl: 1887/3279748 . ISSN   1010-7940. PMID   34453161.
46. Pawade, Tania; Sheth, Tej; Guzzetti, Ezequiel; Dweck, Marc R.; Clavel, Marie-Annick (2019-09-01). "Why and How to Measure Aortic Valve Calcification in Patients With Aortic Stenosis". JACC: Cardiovascular Imaging. 12 (9): 1835–1848. doi: 10.1016/j.jcmg.2019.01.045 . ISSN   1936-878X. PMID   31488252. S2CID   201846410.
47. Vahanian, Alec; Beyersdorf, Friedhelm; Praz, Fabien; Milojevic, Milan; Baldus, Stephan; Bauersachs, Johann; Capodanno, Davide; Conradi, Lenard; De Bonis, Michele; De Paulis, Ruggero; Delgado, Victoria; Freemantle, Nick; Gilard, Martine; Haugaa, Kristina H; Jeppsson, Anders (2022-02-12). "2021 ESC/EACTS Guidelines for the management of valvular heart disease". European Heart Journal. 43 (7): 561–632. doi: 10.1093/eurheartj/ehab395 . ISSN   0195-668X. PMID   34453165.
48. Hutcheson JD, Aikawa E, Merryman WD (April 2014). "Potential drug targets for calcific aortic valve disease". Nature Reviews Cardiology. 11 (4): 218–31. doi:10.1038/nrcardio.2014.1. PMC   4263317 . PMID   24445487.
49. Moura LM, Ramos SF, Zamorano JL, et al. (February 2007). "Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis". Journal of the American College of Cardiology. 49 (5): 554–61. doi:10.1016/j.jacc.2006.07.072. PMC   3951859 . PMID   17276178.
50. Marquis-Gravel G, Redfors B, Leon MB, Généreux P. Medical Treatment of Aortic Stenosis. Circulation. 2016 Nov 29;134(22):1766-1784. doi: 10.1161/CIRCULATIONAHA.116.023997. PMID 27895025.
51. Rutherford SD, Braunwald E (1992). "Chronic ischaemic heart disease". In Braunwald E (ed.). Heart disease: A textbook of cardiovascular medicine (4th ed.). Philadelphia: WB Saunders. pp. 1292–364.
52. Nielsen, Olav W.; Sajadieh, Ahmad; Sabbah, Muhammad; Greve, Anders M.; Olsen, Michael H.; Boman, Kurt; Nienaber, Christoph A.; Kesäniemi, Y. Antero; Pedersen, Terje R.; Willenheimer, Ronnie; Wachtell, Kristian (2016-08-09). "Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS)". Circulation. 134 (6): 455–468. doi:10.1161/CIRCULATIONAHA.115.021213. ISSN   0009-7322.
53. Hans-Joachim Schäfers: Current treatment of aortic regurgitation. UNI-MED Science, Bremen, London, Boston 2013, ISBN   978-3-8374-1406-6.
54. Siemieniuk RA, Agoritsas T, Manja V, et al. (2016). "Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis". BMJ. 354: i5130. doi:10.1136/bmj.i5130. PMC   5040923 . PMID   27683246.
55. Vandvik PO, Otto CM, Siemieniuk RA, Bagur R, Guyatt GH, Lytvyn L, Whitlock R, Vartdal T, Brieger D, Aertgeerts B, Price S, Foroutan F, Shapiro M, Mertz R, Spencer FA (2016). "Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic stenosis at low to intermediate surgical risk: a clinical practice guideline". BMJ. 354: i5085. doi: 10.1136/bmj.i5085 . PMID   27680583. Archived from the original on 2016-10-05.
56. Thourani, VH; Suri, RM; Gunter, RL; Sheng, S; O'Brien, SM; Ailawadi, G; Szeto, WY; Dewey, TM; Guyton, RA; Bavaria, JE; Babaliaros, V; Gammie, JS; Svensson, L; Williams, M; Badhwar, V; Mack, MJ (January 2015). "Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients". The Annals of Thoracic Surgery. 99 (1): 55–61. doi: 10.1016/j.athoracsur.2014.06.050 . PMID   25442986.
57. Foroutan F, Guyatt GH, O'Brien K, et al. (2016). "Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies". BMJ. 354: i5065. doi:10.1136/bmj.i5065. PMC   5040922 . PMID   27683072.
58. Lamelas, J (January 2015). "Minimally invasive aortic valve replacement: the "Miami Method"". Annals of Cardiothoracic Surgery. 4 (1): 71–7. doi:10.3978/j.issn.2225-319X.2014.12.10. PMC   4311159 . PMID   25694981.
59. Sef, D; Krajnc, M; Klokocovnik, T (February 2021). "Minimally invasive aortic valve replacement with sutureless bioprosthesis through right minithoracotomy with completely central cannulation-Early results in 203 patients". Journal of Cardiac Surgery. 36 (2): 558–564. doi: 10.1111/jocs.15257 . PMID   33314301. S2CID   229175207.
60. Sammour, Y; Krishnaswamy, A; Kumar, A; Puri, R; Tarakji, KG; Bazarbashi, N; Harb, S; Griffin, B; Svensson, L; Wazni, O; Kapadia, SR (25 January 2021). "Incidence, Predictors, and Implications of Permanent Pacemaker Requirement After Transcatheter Aortic Valve Replacement". JACC. Cardiovascular Interventions. 14 (2): 115–134. doi: 10.1016/j.jcin.2020.09.063 . PMID   33478630. S2CID   231680789.
61. "Aortic valve stenosis - Treatment - Surgery or Other procedures - Balloon valvuloplasty". Mayo Clinic. 26 February 2021.
62. Christopher M. O'Connor (2005). Managing Acute Decompensated Heart Failure a Clinician's Guide to Diagnosis and Treatment. London: Informa Healthcare. p. 406. ISBN   9780203421345. Archived from the original on 2015-04-02.
63. Spaccarotella C, Mongiardo A, Indolfi C (2011). "Pathophysiology of aortic stenosis and approach to treatment with percutaneous valve implantation". Circulation Journal. 75 (1): 11–19. doi: 10.1253/circj.CJ-10-1105 . PMID   21178291.
64. Stewart BF, Siscovick D, Lind BK, et al. (March 1997). "Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study". Journal of the American College of Cardiology. 29 (3): 630–4. doi: 10.1016/S0735-1097(96)00563-3 . PMID   9060903.
65. clinical Anesthesiology by Edward Morgan^{[ page needed ]}
66. Innasimuthu AL, Katz WE (January 2011). "Effect of bisphosphonates on the progression of degenerative aortic stenosis". Echocardiography. 28 (1): 1–7. doi:10.1111/j.1540-8175.2010.01256.x. PMID   20678125. S2CID   205746869.
67. Nathaniel S, Saligram S, Innasimuthu AL (June 2010). "Aortic stenosis: An update". World Journal of Cardiology. 2 (6): 135–9. doi: 10.4330/wjc.v2.i6.135 . PMC   2999052 . PMID   21160731.
68. Aksoy O, Cam A, Goel SS, et al. (April 2012). "Do bisphosphonates slow the progression of aortic stenosis?". Journal of the American College of Cardiology. 59 (16): 1452–9. doi:10.1016/j.jacc.2012.01.024. PMID   22497825.

External links

• Aortic stenosis at Curlie
• Bonow, Robert O.; Brown, Alan S.; Gillam, Linda D.; Kapadia, Samir R.; Kavinsky, Clifford J.; Lindman, Brian R.; Mack, Michael J.; Thourani, Vinod H. (October 2017). "ACC/AATS/AHA/ASE/EACTS/HVS/SCA/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for the Treatment of Patients With Severe Aortic Stenosis". Journal of the American College of Cardiology. 70 (20): 2566–2598. doi: 10.1016/j.jacc.2017.09.018 . PMID   29054308.